Hemab Collects $157M to Address 'Underserved' Blood Diseases
Hemab, a startup with medicines in testing and development, aims to build the "ultimate coagulation disorders company," according to its CEO.
Innovation in hemophilia has seen significant progress over the last decade, with longer-lasting therapies, antibody drugs, and gene therapies improving patients' ability to control spontaneous bleeds.
However, progress in other bleeding diseases, such as Glanzmann thrombasthenia, Von Willebrand, and Factor VII deficiency, has been slower due to questions about market size and the need for "complex innovations and bioengineering" to develop treatments.
These disorders require more complex innovations and bioengineering to unearth better options.
Hemab's CEO, Sorensen, notes that this has left drugmakers with "less commercial incentive" to develop treatments for these conditions.
Author's summary: Hemab raises $157M to tackle underserved blood diseases.
- Glanzmann thrombasthenia
- Von Willebrand
- Factor VII deficiency
More News
- Benin Rejects Claims of a Coup by Opposition Soldiers
- Congress gridlocked on key issues as year-end deadline looms
- Benin: the government declares coup attempt has been 'foiled'
- Attempted coup d'état in Benin
- Vilnius Airport grounds flights after suspected Belarusian balloons detected
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Tunbridge Wells gridlocked as residents queue for fresh water after five-day outage
- Tartan Army set for ‘big bash’ in Boston with two games in New England
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- Après la tentative de coup d'Etat au Bénin, la menace du pouvoir kaki plus présente que jamais en Afrique